Hennion & Walsh Asset Management Inc. Sells 2,062 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Hennion & Walsh Asset Management Inc. cut its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report) by 13.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,689 shares of the biotechnology company’s stock after selling 2,062 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.06% of Enanta Pharmaceuticals worth $239,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in shares of Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,281 shares during the last quarter. Quest Partners LLC bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $146,000. Diversified Trust Co bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $159,000. Strs Ohio grew its holdings in shares of Enanta Pharmaceuticals by 20.6% during the 4th quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Pennant Investors LP bought a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $330,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $13.14 on Friday. The company has a market capitalization of $278.29 million, a P/E ratio of -2.11 and a beta of 0.60. Enanta Pharmaceuticals, Inc. has a 52-week low of $8.08 and a 52-week high of $22.13. The company’s 50 day moving average price is $12.75 and its 200-day moving average price is $13.04.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.21). The firm had revenue of $17.05 million during the quarter, compared to analyst estimates of $16.47 million. Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. Analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.95 earnings per share for the current year.

Insider Transactions at Enanta Pharmaceuticals

In related news, insider Tara Lynn Kieffer sold 7,266 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $12.33, for a total transaction of $89,589.78. Following the transaction, the insider now owns 32,341 shares in the company, valued at approximately $398,764.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 13.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ENTA shares. JMP Securities reduced their target price on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 7th. StockNews.com raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, HC Wainwright reduced their target price on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.00.

Get Our Latest Research Report on ENTA

About Enanta Pharmaceuticals

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Articles

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.